Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

NCT04180813 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2022-06-23

No results posted yet for this study

Summary

Non-interventional cohort study based on newly collected data under routine medical practice of a total of 500 Diabetes Mellitus, Type 2 patients

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Linagliptin

drug

DRUG

Acarbose

drug

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-04
Primary Completion
2021-07-11
Completion
2021-07-11

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04180813 on ClinicalTrials.gov